Cytokinetics, Incorporated (CYTK)

Cytokinetics topped EPS expectations while revenue fell year over year in the second fiscal quarter of 2026, reported August 6, 2026. EPS came in at -$1.50 versus the -$1.63 estimate (+8.0%), down from -$1.12 a year ago, as revenue declined 52.2% to roughly $31.9 million (from $66.8 million a year ago). Despite the lower top line, gross profit was about $29.2 million and gross margin held near 91%. Operating income was a loss of roughly $175.9 million, and the company posted a net loss of about $198.8 million, with net income down 47.9% year over year from a loss of $134.4 million. Consensus for the next period calls for EPS of -$1.45.